

Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in special operations veterans with traumatic brain injuries

Received: 15 December 2025

Revised: 1 July 2026

Accepted: 24 July 2026

Published online: 12 August 2026

Cite this article as: Faerman, A., Lissemore, J.I., Geoly, A.D. *et al.* Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in special operations veterans with traumatic brain injuries. *Transl Psychiatry* (2026). <https://doi.org/10.1038/s41398-026-04327-5>

Afik Faerman, Jennifer I. Lissemore, Andrew D. Geoly, Kirsten N. Cherian, Malvika Sridhar, Bora Kim, John P. Coetzee, Lauren Anker, Ahmed Shamma, Jakob N. Keynan, Randi E. Brown, Angela Phillips, Ashley Jester, Nicholas J. Bassano, Jennifer Keller, Flint M. Espil, Ian H. Kratter, Camarin E. Rolle & Nolan R. Williams

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

If this paper is publishing under a Transparent Peer Review model then Peer Review reports will publish with the final article.

Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in Special Operations Veterans with traumatic brain injuries

Afik Faerman, PhD* ¹, Jennifer I. Lissemore, PhD* ¹, Andrew D. Geoly, MS ¹, Kirsten N. Cherian, PhD ¹, Malvika Sridhar, MS ¹, Bora Kim, MD ¹, John P. Coetzee, PhD ^{1,2}, Lauren Anker, PhD ¹, Ahmed Shamma, BS ¹, Jakob N. Keynan, PhD ¹, Randi E. Brown, PhD ¹, Angela Phillips, PhD ¹, Ashley Jester, PhD ³, Nicholas J. Bassano, BS ¹, Jennifer Keller, PhD ¹, Flint M. Espil, PhD ¹, Ian H. Kratter, MD PhD ¹, Camarin E. Rolle, PhD** ¹, Nolan R. Williams, MD**† ¹

1 Department of Psychiatry & Behavioral Sciences, Stanford University Medical Center, Stanford, CA, 94305, USA

2 WOMEN CoE, Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto, CA, USA

3 Woods Hole Oceanographic Institution, Woods Hole, MA, 02543, USA

*Co-first

** Co-senior

† Dr. Nolan Williams passed away prior to the submission of this manuscript. All other authors affirm that Dr. Nolan Williams made significant contributions to the conception, design, and interpretation of the work and that this submission is consistent with his intentions. This work is dedicated to his memory.

Corresponding Author:

Camarin E. Rolle, PhD

Scientific Director, Brain Stimulation Lab

Clinical Assistant Professor, Department of Psychiatry and Behavioral Sciences, Stanford University

401 Quarry Rd.

Stanford, CA 94304

Email: crolle@stanford.edu

ABSTRACT

Traumatic brain injury (TBI) can result in chronic functional disability and is associated with persistent psychiatric symptoms, including posttraumatic stress disorder (PTSD), depression, and anxiety. Ibogaine, an oneirogenic alkaloid with unique pharmacological properties, has shown initial promise as a potential treatment for TBI-related sequelae. We previously observed large improvements in functional and psychiatric outcomes up to one month after a single treatment with magnesium-ibogaine in male U.S. Special Operations Veterans with a history of TBI. However, further evidence on the durability of these effects is needed. In this prospective long-term follow-up study, we evaluated the persistence of these clinical improvements over the subsequent year. Participants underwent comprehensive baseline and post-treatment assessments, with follow-up evaluations conducted at 3, 6, 9, and 12 months. Of 30 participants treated with magnesium-ibogaine, 25 completed the 12-month follow-up assessments. Outcome measures included a self-report measure of functional disability and clinician-administered assessments of psychiatric symptoms. Linear mixed-effects models demonstrated robust and sustained reductions in disability, PTSD, depression, and anxiety symptoms through 12 months post-treatment (all $p < 0.001$ after correction for multiple comparisons), with large effect sizes (Cohen's $d \geq 2.18$ at 12 months). In participants who achieved remission immediately post-treatment, survival analyses estimated the probability of sustained remission at 12 months as 84% for PTSD, 66% for depression, and 61% for anxiety. Notably, most participants reported using other psychedelic substances or pursuing other interventions during the follow-up period, which should be considered when interpreting long-term symptom trajectories. In this naturalistic cohort, durable, clinically meaningful symptom improvements were observed in individuals with TBI up to 12 months after ibogaine treatment. Further investigation through randomized controlled trials is warranted to validate these promising preliminary results and clarify the causal contributions of ibogaine treatment, subsequent interventions, and their combination.

Traumatic brain injury (TBI) is a significant and growing health problem that can be associated with lasting emotional, behavioral, and cognitive deficits with large public health costs^{1–3} and is among the greatest contributors of all trauma-related injuries to death and disability globally⁴. A substantial proportion of individuals who suffer a mild or moderate TBI develop a constellation of symptoms that can last for months or years, with long-term impacts on functioning across many domains of life, including work, relationships, cognition, emotion, and overall quality of life⁵. Despite ongoing clinical management of chronic symptoms², psychiatric and functional limitations may persist³, highlighting the need for new treatments.

Psychedelic medicine is transforming our understanding of rapid-acting treatment options in psychiatry, although investigations into the long-term outcomes of psychedelic treatments are needed^{6–8}. Ibogaine in particular is an oneirogenic alkaloid that shows promise as a rapid-acting treatment, and preliminary studies have shed light on the potential durability of its therapeutic effects. For example, patients with opioid use disorder reported reductions in problematic drug use one year after ibogaine treatment^{9,10}, with secondary findings of sustained reductions in self-reported depression¹⁰. Similarly, a clinical chart review study in veterans found reductions in self-reported PTSD, depression, and anxiety symptoms for up to six months after ibogaine treatment paired with 5-MeO-DMT¹¹.

Recently, Cherian et al.¹² found that a single treatment with MISTIC (Magnesium-Ibogaine: the Stanford Traumatic Injury to the CNS) led to significant improvements in disability severity, as well as clinician-rated measures of post-traumatic stress disorder (PTSD), depression, and anxiety symptoms in Special Operations Veterans (SOVs) with a history of TBI, with benefits sustained at 1-month follow-up. Additionally, there was no evidence of negative effects of MISTIC on cognitive functions. Whether these therapeutic benefits endure beyond the first month, however, remains unknown. In the current prospective long-term follow-up study, participants from Cherian et al.¹² were reassessed by clinicians at approximately 3, 6, 9, and 12 months posttreatment to evaluate the durability of MISTIC effects.

Methods

Participants. Thirty male SOVs underwent baseline and posttreatment assessments. Inclusion criteria were age between 18 and 70 years, history of combat or blast exposure, history of TBI (based on Department of Defense TBI classification¹³), no contraindication to magnetic resonance imaging (MRI), ability to travel to Stanford, and ability to provide written informed consent. Exclusion criteria included a history of neurological disorders (except TBI), psychotic symptoms or disorders, risk for suicidal behavior, cardiovascular problems, liver or kidney problems, pregnancy, clinical abnormalities on screening physical exam that could impact safety or study integrity, and participation in a recent/ongoing relevant study. See Cherian et al.¹² for CONSORT and further details. All participants provided written informed consent, and research procedures were approved by the Stanford University Institutional Review Board.

At baseline, 15 participants met the criteria for major depressive disorder, 14 for anxiety disorder, and 23 for posttraumatic stress disorder. Nineteen participants reported prior use of psychedelic drugs; however, the nature of use differed notably, from a single use in younger ages to periods of regular use. Additionally, 21 participants had received formal mental health treatment before the ibogaine trial, and 19 participants reported a history of treatment with psychotropic medication in particular. The average ($\pm$ standard deviation) number of prior TBIs reported was

38.6 ± 52.4. TBIs were mostly mild (n=28), with two participants reporting a history of moderate (n=1) or moderately severe TBI (n=1). Participants enrolled in the study an average of 7.7 ± 4.8 years after military discharge and 15.2 ± 5.9 years after their most severe TBI (range: 8 - 28 years).

Treatment. Participants independently elected to undergo ibogaine treatment at Ambio Life Sciences in Mexico, facilitated by Veterans Exploring Treatment Solutions (VETS), Inc., a nonprofit organization. VETS, Inc. informed potential participants about the study and referred interested individuals to the Stanford research team. All psychiatric and neuroimaging assessments, both pre- and post-treatment, were conducted by the Stanford team - either in-person at Stanford University or virtually. All aspects of ibogaine treatment took place at Ambio Life Sciences, as ibogaine use is restricted in the United States. VETS, Inc. funded treatment, travel, and accommodation expenses.

As part of Ambio's internal application process, medical screenings were conducted to rule out contraindicated medical conditions and avoid drug-drug interactions. To mitigate risks of Q-T interval prolongation^{12,14}, magnesium sulfate (1g) was administered intravenously while participants were in a fasting state 1-2 hours before ibogaine dosing. Ibogaine was administered orally, starting with an initial test dose of 2-3 mg/kg. Depending on response, treatment doses of up to a total of <14 mg/kg of oral ibogaine were administered in 3 or 4 doses across a 2-hour period beginning approximately 40 minutes after the initial test dose. An additional dose of magnesium sulfate was delivered intravenously approximately 12 hours after ibogaine dosing. One participant received an additional 4mg/kg dose of ibogaine 12 hours after the first ibogaine dose due to insufficient treatment effects. Participants were monitored for 72 hours after dosing, as the effects of ibogaine can last 24-72 hours¹⁵. For further information and a detailed description of the full MISTIC protocol, see Cherian et al.¹².

As part of Ambio's program, ibogaine is typically followed a few days later by 5-MeO-DMT, but participants in the current study refrained from using 5-MeO-DMT until after the 1-month measures had been collected. Also as part of Ambio's program, participants were partnered with a coach for intention setting, practicing navigation techniques for the psychedelic experience, managing expectations, exploring relationship dynamics, implementing supportive change in the home, and physical preparation. Additionally, participants received a workbook recommended to use before and after the retreat. After treatment, coaches assist with processing emotions, helping to define meaning, and integrating insights from the treatment experience into participants' everyday lives. Coaching does not involve diagnosing, delving into past traumas, or medication-based approaches to healing. Both coaching and workbook use were voluntary and varied substantially across participants (mean preparation hours = 2.7 ± 0.8, range: 1-4.3; mean integration hours = 4.1 ± 3.0, range: 0-13.5).

Structured Assessments. The initial in-person assessments were performed at baseline (2-3 days pre-MISTIC), immediately (4-5 days) post-MISTIC, and 1-month post-MISTIC. Follow-up assessments were performed approximately 3-, 6-, 9-, and 12-months post-MISTIC via teleconferencing. Self-report and clinician-administered measurements included the World Health Organization Disability Assessment Schedule, 2nd Edition (WHODAS-2.0¹⁶; functional disability), Clinician-Administered PTSD Scale for DSM-5 (CAPS-5¹⁷; posttraumatic stress symptom

severity), Montgomery–Åsberg Depression Rating Scale (MADRS¹⁸; depression symptom severity), and Hamilton Anxiety Rating Scale (HAM-A¹⁹; anxiety symptom severity). TBI severity was assessed using the Ohio State University Screening for TBI exposure²⁰, and the lifetime incidence of TBIs was assessed using the Boston Assessment of Traumatic Brain Injury–Lifetime (BAT-L)¹³. Combat exposure was quantified by the Combat Exposure Scale (CES)²¹, a retrospective clinician-administered seven-item scale. Items assess the frequency, duration, or degree of exposure to combat-related stressors (being under enemy fire, firing a weapon at the enemy, being surrounded by the enemy, witnessing casualties, handling dead bodies, encountering hostility from civilians, and sustaining or witnessing injuries), with total scores ranging from 0 to 41. For further details about the measures used, see Cherian et al.¹².

Data Analysis. Analysis followed the approach used by Cherian et al.¹²; Linear mixed-effects models were performed for each outcome measure (WHODAS, CAPS-5, MADRS, and HAM-A), with outcome measure scores as the dependent variable and time point (baseline, immediate post-MISTIC, 1-, 3-, 6-, 9-, and 12-months post-MISTIC) as a categorical independent variable, with a fixed slope and random intercept, and age, CES, and total number of reported TBIs included as fixed effects. Contrasts between baseline and 12-month follow-up (primary outcome, registered at osf.io: <https://osf.io/uxjsp/>) and each additional post-MISTIC follow-up (secondary outcomes) were performed using the MATLAB hypothesis test on fixed-effect coefficients of LME models. False discovery rate (FDR) correction was applied for multiple comparisons. As noted in Cherian et al.¹², no power calculations were performed as this was an observational study.

A secondary Kaplan-Meier survival analysis was performed to assess the time to relapse across PTSD, depression, and anxiety diagnoses for participants meeting MINI diagnostic criteria at baseline, who also met remission criteria immediately post-MISTIC. Remission was defined as a loss of diagnosis and CAPS-5 total score <12 for PTSD, MADRS <8 for depression, and HAM-A <8 for anxiety¹². Relapse was defined as the first recorded departure from remission criteria for a respective diagnosis¹², and cases that were lost to follow-up or never experienced a relapse were censored at their last recorded observation. For survival analyses of the duration of response, response was defined as a reduction of at least 10 points on the CAPS-5 for PTSD, 50% on the MADRS for depression, and 50% on the HAM-A for anxiety¹² (see Supplement). See Supplement for further details and analyses of associations between baseline characteristics and long-term outcomes. All descriptive statistics are shown as mean $\pm$ standard deviation, unless noted otherwise.

Results

Of the 30 participants treated with MISTIC, 27 completed at least one long-term follow-up assessment (age = 44.8 ± 7.1 years). At the 12-month post-MISTIC follow-up (primary outcome), 25 of the 30 participants completed self-report and clinician-administered assessments. Of them, 23 used at least one psychedelic substance (either via microdosing, full dose, or both) between the 1-month and 12-month follow-ups (Table S1). This included 19 participants who reported 5-MeO-DMT use after the 1-month visit, 18 of them in the context of a retreat. In addition, 12 participants engaged in some form of therapy or counselling during the 12-month follow-up period, while only 3 participants reported any psychotropic medication use (Table S1).

Functional disability, PTSD, depression, and anxiety scores were all significantly lower 12 months post-MISTIC compared to pre-MISTIC after correction for multiple comparisons (all $p_{corrected} < 0.001$), with large effect sizes (all Cohen's $d > 2.17$). Post-MISTIC scores were also significantly lower than pre-MISTIC scores at 3-, 6-, and 9-month follow-ups (all $p_{corrected} < 0.001$), with large effect sizes (all Cohen's $d > 1.80$). Model residuals were approximately normally distributed. See Figure 1 for individual score trajectories and Table 1 for linear mixed-effects model results.

Long-term outcomes were similar in participants who did and did not pursue additional interventions during the follow-up period (including structured mental health treatment, psychotropic medication, 5-MeO-DMT, psilocybin, ibogaine, or ayahuasca; Table S1). Significant long-term outcomes were also observed in sensitivity analyses, including only participants who met diagnostic criteria for PTSD, depression, or anxiety disorder at baseline (Table S2). Additionally, sensitivity analyses confirmed that the results were not driven by participants with moderate to moderately severe TBI: when analyses were restricted to participants with a history of mild TBI, all effects remained significant (all Cohen's $d > 1.7$; Table S3).

Secondary Kaplan-Meier survival analyses were completed for participants who achieved remission from PTSD (N=19 of 23), depression (N=11 of 15), or anxiety (N=11 of 14) immediately post-MISTIC (Figure 2, Table S4). Mean times to relapse were 10.7 (SE=0.8), 10.3 (SE=1.1), and 9.1 (SE=1.3) months for PTSD, depression, and anxiety, respectively, with no significant differences in time to relapse by diagnosis ($\chi^2 = 1.7$, $df = 2$, $p = 0.43$). KM-estimated probabilities of maintained remission 12 months following acute remission to MISTIC were 84%, 66%, and 61%, for PTSD, depression, and anxiety, respectively. See Supplement for Kaplan-Meier estimates of the duration of response for PTSD, depression, and anxiety.

Discussion

In this prospective, long-term follow-up study, clinically meaningful reductions in disability, PTSD, depression, and anxiety symptoms persisted 12 months after a single session of MISTIC. Significant and large improvements across all symptom domains were observed at 3, 6, 9, and 12 months after treatment, with effect sizes remaining large at 12 months (all Cohen's $d > 2$). Among participants who achieved remission immediately after treatment, the probability of sustained remission over 12 months exceeded 80% for PTSD and 60% for depression and anxiety. Although these findings are encouraging, this was an open-label observational study with a modest sample size; larger randomized controlled trials are needed to test the replicability and specificity of these long-term effects.

Multiple factors may have contributed to the durability of symptom improvements observed here. Recent findings from our group suggest that magnesium-ibogaine is associated with both structural and functional brain changes up to 1-month post treatment, including increased cortical thickness and reduced predicted brain age²², altered cortical oscillations and neural complexity²³, and changes in regional cerebral blood flow and functional connectivity²⁴. Furthermore, some of these biological changes were associated with clinical improvement^{23,24}. Subjective effects may also provide further context. The intensity of mystical experiences during magnesium-ibogaine was associated with greater reductions in PTSD severity both immediately and one month after treatment, as well as larger reductions in peak alpha frequency at one month²⁵. Qualitative work further suggests that thematic reprocessing of traumatic experiences in the context of

magnesium-ibogaine, coupled with altered self-perception, profound sense of resolution and forgiveness, and an embodied sense of neural healing and somatic relief may represent meaningful therapeutic processes that occur with magnesium-ibogaine²⁶. While the available evidence does not yet support a definitive mechanistic account, these convergent objective and subjective findings provide a neurobehavioral framework to consider in future studies.

The findings of the current study add to a growing body of evidence that psychedelic and psychedelic-assisted treatments may have therapeutic potential for a variety of psychiatric conditions²⁷. Emerging evidence, particularly on the antidepressant effects of psilocybin^{28–31}, suggests that psychedelic and psychedelic-assisted treatment effects may also persist long-term, although relatively few studies have prospectively evaluated outcomes beyond 6 months^{32–34}. It is imperative for the field to investigate the long-term durability of such treatments.

Limitations. In addition to ibogaine, a variety of factors may have contributed to the durability of improvements in disability, posttraumatic stress, depression, and anxiety observed in this study. During follow-up, some participants sought treatment through psychotherapy or psychiatric medication, attended self-help seminars and workshops, and experienced significant life events. In addition, 92% of participants reported some psychedelic use between 1 and 12 months after the initial retreat (Table S1), which is an important limitation to consider when interpreting the durability of effects. Future studies are needed to identify specific factors that may interact with MISTIC durability. Nevertheless, considering that the participants in this study continued to suffer from substantial psychiatric, functional, and cognitive symptoms years after sustaining their TBIs, the durability of the large clinical effects observed here is encouraging. Although we did not control for participants' specific engagement in activities and treatments or significant life events between the 1-month and 12-month follow-ups, the mixed-effects models included participant-specific random intercepts, which accounted to some extent for individual variability. Additionally, exploratory subgroup analyses stratified by specific post-treatment intervention types showed that participants who did not pursue a given intervention nevertheless demonstrated substantial long-term improvements across outcomes (Table S1).

Given the open-label design of this initial study, expectancy effects may also have contributed to the observed clinical outcomes. However, several observations suggest that the large, persisting symptom improvements observed in this study are unlikely to be caused by expectancy effects alone. We previously found that symptom improvements were accompanied by improvements in objective neuropsychological test scores that are less sensitive to placebo effects^{12,35}. Additionally, placebo responses tend to be less durable than true drug responses^{36,37}. In prior work, we also observed neural correlates of ibogaine-related symptom improvements that differed from those associated with placebo responses²³. Nonetheless, controlled trials are needed to adequately determine the extent to which expectancy contributed to the present findings.

While most participants reported some use of psychedelic compounds after treatment with ibogaine, the nature of that use was highly varied, and the current study was not designed to evaluate substance use risk. Although classic psychedelics are generally thought to have a low likelihood of dependence or abuse³⁸, the relationship between naturalistic psychedelic use and the risk of problematic use varies across substances and study contexts^{39,40}. Dedicated

prospective studies are needed to characterize the risk profile of ibogaine and other psychedelics in clinical trial and retreat settings.

Conclusions. In this 12-month follow-up study, most participants with a history of TBI showed large and sustained improvements in disability, PTSD, depression, and anxiety after a single MISTIC treatment, with high rates of continued response and remission at 12 months. These findings should be interpreted in light of the open-label design and concurrent use of additional psychedelics during follow-up. The magnitude and persistence of improvement observed here supports continued investigation of magnesium-ibogaine in rigorous controlled studies. Although regulatory restrictions for ibogaine currently limit access and impose a high travel and financial burden, the present findings of lasting therapeutic benefits for veterans with TBI following ibogaine treatment warrant further studies to test these effects in larger, controlled trials.

ARTICLE IN PRESS

Author Contributions. A.F. performed screening, psychological assessments, completed and supervised related scoring and data entry, provided guidance and feedback on clinical interpretation, and co-lead the writing and subsequent revision of the paper. J.I.L. designed, performed and interpreted the statistical analyses and co-lead the writing and subsequent revision of the paper. A.D.G. designed, performed and interpreted statistical analyses and participated in the writing and subsequent revision of the paper. K.N.C. performed screening, psychological assessments, completed and supervised related scoring and data entry, and participated in the writing and subsequent revision of the paper. M.S. and A.S. assisted with study design, supported study execution at Stanford and reviewed the paper. B.K. assisted with study design and participated in the writing and subsequent revision of the paper. J.P.C. assisted with study design, supported study execution at Stanford and reviewed the paper. L.A. supported study execution at Stanford, psychological assessments, scoring assessments, data entry, and reviewed the paper. J.N.K. designed the statistical analyses and reviewed the paper. R.E.B. assisted with scoring assessments and data entry and reviewed the paper. A.P. and N.J.B. supported study execution at Stanford and reviewed the paper. A.J. provided statistical consultation, reviewed, critiqued, and interpreted the statistical analyses, and reviewed the paper. J.K. contributed to the design of the standardized assessments and reviewed the paper. F.M.E. provided guidance on clinical measures and reviewed and critiqued the paper. I.H.K. assisted with study design, supported study execution at Stanford, and reviewed the paper. C.E.R. performed a literature review, contributed to the critique and revision of the paper, supervised all data analysis, and assumed the role of protocol director following N.R.W.'s passing. N.R.W. conceived the study; supervised study design, budgeting and execution at Stanford; was protocol director of the study until his passing. All authors approved the final manuscript. A.F. and J.I.L. were co-first authors; C.E.R. and N.R.W. were co-senior authors.

Ethics approval and consent to participate. All research methods were performed in accordance with the Declaration of Helsinki. All participants provided written informed consent, and research procedures were approved by the Stanford University Institutional Review Board (54095).

Data availability. Owing to the sensitivity of psychiatric patient data, our IRB requires individualized review before data sharing. We have produced anonymized data related to the present findings for sharing with all scientists with research and data safeguarding plans that comport with Stanford University guidelines. Please contact C. Rolle at crolle@stanford.edu with data-sharing requests.

Code availability. Linear mixed-effects model analyses were performed in MATLAB R2023a. Secondary Kaplan-Meier survival analyses and exploratory analyses were performed in R (versions 4.3.1 and 4.3.2). Code will be made available upon reasonable request.

Acknowledgements and Funding. This work was made possible by the generous donations of Steve and Genevieve Jurvetson, the Effie and Wofford Cain Foundation, Eugene Jhong, the Saisei Foundation, Laura Keller, and by support from and collaboration with Veterans Exploring Treatment Solutions (VETS), Inc., a non-profit organization committed to advancing healthcare

options for veterans. This work was also supported by a Canadian Institutes of Health Research Fellowship to J.I.L. (176536). The funders played no role in study design, execution, data analysis, or preparation of the manuscript.

Conflicts of interest. N.R. Williams is a named inventor on Stanford-owned intellectual property relating to magnesium-ibogaine; he has served on scientific advisory boards for Otsuka, NeuraWell, Magnus Medical, Soneira, and Nooma as a paid advisor, and he has equity/stock options in NeuraWell, Soneira, and Nooma. I.H. Kratter is a named inventor on Stanford-owned intellectual property relating to magnesium-ibogaine; he currently receives a salary from Soneira and consulting fees from Neuralink and Salma Health, and he has equity/stock options in Soneira and Salma Health. A.D. Geoly and J.P. Coetzee are named inventors on Stanford-owned intellectual property relating to magnesium-ibogaine. The remaining authors declare no competing interests.

References.

- 1 Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung Y-C, Punchak M *et al.* Estimating the global incidence of traumatic brain injury. *Journal of Neurosurgery* 2019; **130**: 1080–1097.
- 2 Levin HS, Diaz-Arrastia RR. Diagnosis, prognosis, and clinical management of mild traumatic brain injury. *The Lancet Neurology* 2015; **14**: 506–517.
- 3 Howlett JR, Nelson LD, Stein MB. Mental Health Consequences of Traumatic Brain Injury. *Biological Psychiatry* 2022; **91**: 413–420.
- 4 Rubiano AM, Carney N, Chesnut R, Puyana JC. Global neurotrauma research challenges and opportunities. *Nature* 2015; **527**: S193–S197.
- 5 Report to Congress on Traumatic Brain Injury in the United States: Epidemiology and Rehabilitation. . National Center for Injury Prevention and Control; Division of Unintentional Injury Prevention: Atlanta, GA, 2015https://www.cdc.gov/traumaticbraininjury/pdf/tbi_report_to_congress_epi_and_rehab-a.pdf.
- 6 Allen J, Dames SS, Foldi CJ, Shultz SR. Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential. *Mol Psychiatry* 2024; **29**: 671–685.
- 7 Brody DL, Siddiqi SH. An ancient psychedelic for traumatic brain injury. *Nat Med* 2024; **30**: 342–343.
- 8 Volkow ND, Gordon JA, Wargo EM. Psychedelics as Therapeutics—Potential and Challenges. *JAMA Psychiatry* 2023; **80**: 979.
- 9 Davis AK, Barsuglia JP, Windham-Herman A-M, Lynch M, Polanco M. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. *Journal of Psychedelic Studies* 2017; **1**: 65–73.

- 10 Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. *The American Journal of Drug and Alcohol Abuse* 2018; **44**: 37–46.
- 11 Davis AK, Xin Y, Sepeda N, Averill LA. Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico. *The American Journal of Drug and Alcohol Abuse* 2023; **49**: 587–596.
- 12 Cherian KN, Keynan JN, Anker L, Faerman A, Brown RE, Shamma A *et al.* Magnesium–ibogaine therapy in veterans with traumatic brain injuries. *Nat Med* 2024. doi:10.1038/s41591-023-02705-w.
- 13 Fortier CB, Amick MM, Grande L, McGlynn S, Kenna A, Morra L *et al.* The Boston Assessment of Traumatic Brain Injury–Lifetime (BAT-L) semistructured interview: evidence of research utility and validity. *The Journal of head trauma rehabilitation* 2014; **29**: 89.
- 14 Ona G, Rocha JM, Bouso JC, Hallak JEC, Borràs T, Colomina MT *et al.* The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020). *Psychopharmacology (Berl)* 2022; **239**: 1977–1987.
- 15 Alper KR. Ibogaine: a review. *Alkaloids Chem Biol* 2001; **56**: 1–38.
- 16 Ustun, T. B., Kostanješek, N., Chatterji, S., Rehm, J. & World Health Organization. *Measuring Health and Disability: manual for WHO Disability Assessment Schedule (WHODAS-2.0)*. WHOapps.who.int/iris/handle/10665/43974.
- 17 Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG *et al.* The Clinician-Administered PTSD Scale for DSM–5 (CAPS-5): Development and initial psychometric evaluation in military veterans. *Psychological Assessment* 2018; **30**: 383–395.
- 18 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979; **134**: 382–389.
- 19 Shear MK, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Otto MW *et al.* Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). *Depress Anxiety* 2001; **13**: 166–178.
- 20 Corrigan JD, Bogner J. Initial reliability and validity of the Ohio State University TBI identification method. *The Journal of head trauma rehabilitation* 2007; **22**: 318–329.
- 21 Keane TM, Fairbank JA, Caddell JM, Zimering RT, Taylor KL, Mora CA. Clinical evaluation of a measure to assess combat exposure. *Psychological Assessment: A Journal of Consulting and Clinical Psychology* 1989; **1**: 53–55.
- 22 Geoly AD, Coetzee JP, Buchanan DM, Struckmann W, Kim B, Sridhar M *et al.* Increased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocol. *iScience* 2026; : 115121.

- 23 Lissemore JI, Chaiken A, Cherian KN, Buchanan D, Espil F, Keynan JN *et al.* Magnesium–ibogaine therapy effects on cortical oscillations and neural complexity in veterans with traumatic brain injury. *Nat Mental Health* 2025; **3**: 918–931.
- 24 Sridhar M, Azeez A, Geoly AD, Lissemore JI, Faerman A, Cherian K *et al.* Neural correlates of ibogaine: Evidence from functional neuroimaging of military veterans. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging* 2026; : S2451902226000455.
- 25 Brown RE, Lissemore JI, Shinozuka KF, Coetzee JP, Faerman A, Olash CA *et al.* Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans. *Journal of Affective Disorders* 2026; **395**: 120722.
- 26 Olash C, Buchanan DM, Brown R, Faerman A, Cherian K, Lin G *et al.* Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders. *npj Mental Health Res* 2026; **5**: 8.
- 27 Yao Y, Guo D, Lu T-S, Liu F-L, Huang S-H, Diao M-Q *et al.* Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. *Psychiatry Research* 2024; **335**: 115886.
- 28 Goodwin GM, Nowakowska A, Atli M, Dunlop BW, Feifel D, Hellerstein DJ *et al.* Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder. *J Clin Psychiatry* 2025; **86**. doi:10.4088/JCP.24m15449.
- 29 Ellis S, Bostian C, Donnelly A, Feng W, Eisen K, Lean M *et al.* Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study. *Journal of Affective Disorders* 2025; **389**: 119655.
- 30 Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW *et al.* Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. *J Psychopharmacol* 2022; **36**: 151–158.
- 31 Davis AK, DellaCrosse MA, Sepeda ND, Levin AW, Cosimano M, Shaub H *et al.* Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder. *JPS* 2025; **9**: 320–329.
- 32 Solaja I, Haldane K, Mason N, Weiss B, Xu X, Xu M *et al.* Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition/creativity, emotional processing and personality. *Neuroscience & Biobehavioral Reviews* 2024; **158**: 105570.
- 33 Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK. Long-term effects of psychedelic drugs: A systematic review. *Neuroscience & Biobehavioral Reviews* 2020; **113**: 179–189.
- 34 Luoma JB, Chwyl C, Bathje GJ, Davis AK, Lancelotta R. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. *J Psychoactive Drugs* 2020; **52**: 289–299.

- 35 Calamia M, Markon K, Tranel D. Scoring Higher the Second Time Around: Meta-Analyses of Practice Effects in Neuropsychological Assessment. *The Clinical Neuropsychologist* 2012; **26**: 543–570.
- 36 Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J *et al.* Use of Pattern Analysis to Predict Differential Relapse of Remitted Patients With Major Depression During 1 Year of Treatment With Fluoxetine or Placebo. *Arch Gen Psychiatry* 1998; **55**. doi:10.1001/archpsyc.55.4.334.
- 37 Quitkin FM. Identification of True Drug Response to Antidepressants: Use of Pattern Analysis. *Arch Gen Psychiatry* 1984; **41**: 782.
- 38 Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. *J Psychopharmacol* 2022; **36**: 258–272.
- 39 Glynos NG, Aday JS, Kruger D, Boehnke KF, Lake S, Lucas P. Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey. *Front Psychiatry* 2024; **15**: 1349565.
- 40 Rabinowitz J, Lev-Ran S, Gross R. The association between naturalistic use of psychedelics and co-occurring substance use disorders. *Front Psychiatry* 2023; **13**: 1066369.

Table 1. Linear mixed-effects model results showing long-term improvements in functional disability, PTSD, depression, and anxiety after a single treatment with Magnesium-Ibogaine: the Stanford Traumatic Injury to the CNS (MISTIC).





		WHODAS-2.0	CAPS-5	MADRS	HAM-A
Baseline	N	30	30	30	30
	M (SD)	30.2 (14.7)	31.7 (12.5)	25.6 (8.7)	20.8 (8.5)
Immediate-Post	N	30	30	30	30
	M (SD)	19.9 (16.3)	3.9 (4.8)	2.8 (3.3)	3.6 (3.4)
	<i>F</i>	29.19	319.97	358.30	230.62
	<i>p_{corrected}</i>	<.001	<.001	<.001	<.001
	<i>d</i>	0.74	2.30	2.65	2.06
1 Month	N	26	30	30	30
	M (SD)	5.1 (8.1)	4.8 (7.9)	3.8 (6.0)	3.9 (4.6)
	<i>F</i>	123.02	297.67	328.97	230.62
	<i>p_{corrected}</i>	<.001	<.001	<.001	<.001
	<i>d</i>	2.20	2.54	2.80	2.13
3 Months	N	8	10	10	10
	M (SD)	4.8 (5.9)	3.1 (2.4)	1.8 (2.6)	3.5 (2.7)
	<i>F</i>	55.54	173.46	201.51	121.40
	<i>p_{corrected}</i>	<.001	<.001	<.001	<.001
	<i>d</i>	2.26	3.46	4.45	2.58
6 Months	N	17	21	21	21
	M (SD)	8.5 (8.8)	5.6 (6.5)	5.2 (6.7)	4.5 (5.5)
	<i>F</i>	69.97	221.28	229.74	166.54
	<i>p_{corrected}</i>	<.001	<.001	<.001	<.001
	<i>d</i>	2.05	2.17	2.83	2.10
9 Months	N	15	17	17	17
	M (SD)	7.3 (7.2)	4.6 (5.2)	4 (4.1)	4.5 (4.5)
	<i>F</i>	69.49	234.91	250.64	160.88
	<i>p_{corrected}</i>	<.001	<.001	<.001	<.001
	<i>d</i>	1.81	2.94	4.08	2.06
12 Months	N	25	25	25	25
	M (SD)	8.4 (12.3)	4.4 (6.9)	4.9 (5.5)	3.7 (3.6)
	<i>F</i>	90.68	284.83	265.90	203.34
	<i>p_{corrected}</i>	<.001	<.001	<.001	<.001
	<i>d</i>	2.27	2.72	3.35	2.18


Results are presented as raw mean (M) and standard deviation (SD). Degrees of freedom: (1, 129) for WHODAS; (1, 139) for CAPS-5, MADRS, and HAM-A. Cohen's *d* reflects the effect size for the contrast between each post-treatment time point and baseline.

Abbreviations: CAPS-5 = Clinician Administered PTSD Scale for DSM-5; HAM-A = Hamilton Anxiety Rating Scale; MADRS = Montgomery-Åsberg Depression Rating Scale; WHODAS-2.0 = World Health Organization Disability Assessment Schedule, 2nd Edition

Figure 1. Individual score trajectories for (a) WHODAS-2.0 (percentage disability), (b) CAPS-5 (posttraumatic stress), (c) MADRS (depression), and (d) HAM-A (anxiety). Clinical interpretation thresholds were added for each measure. Dashed blue lines reflect missing data at some time points in between follow-up assessments. The dashed red line represents the mean score at each time point. *Abbreviations:* CAPS-5 = Clinician-Administered PTSD Scale for DSM-5; HAM-A = Hamilton Anxiety Rating Scale; MADRS = Montgomery-Åsberg Depression Rating Scale; WHODAS-2.0 = WHO Disability Assessment Schedule, 2nd Edition.

Figure 2. Kaplan-Meier curves of the duration of remission for post-traumatic stress disorder (PTSD; red), major depressive disorder (MDD; blue), and anxiety (yellow) diagnoses as a function of time (months) following MISTIC. Solid lines represent the overall survival estimate, hatched marks indicate censored participants, and dashed lines represent 95% confidence intervals. Number at risk and cumulative number censored tables provide accompanying information. Remission criteria for PTSD: CAPS-5 <12, MDD: MADRS <8, anxiety: HAM-A <8, and a loss of diagnosis.





Number at Risk

PTSD	19	15	15	15	14
MDD	11	8	8	7	6
Anxiety	11	8	8	7	6

Cumulative Number Censored

PTSD	0	2	2	2	16
MDD	0	2	2	3	8
Anxiety	0	1	1	1	7